Regorafenib counteracts this by modulating the IFN-γ/NSDHL/SREBP1/TGF-β1 axis, restoring ICI efficacy in HCC (Xie et al., 2023[126]), representing a novel strategy for overcoming IFN-γ-mediated immunosuppression in cancer therapy. Here, IFNG is linked to cancer.